Dyne Therapeutics announced on Monday that its experimental drug targeting Duchenne muscular dystrophy (DMD) has successfully met its primary endpoint in a late-stage clinical trial. This...
Dyne Therapeutics announced on October 16, 2023, that its experimental drug for **Duchenne muscular dystrophy** (DMD) has successfully met the primary endpoint in a late-stage clinical...
Sarepta Therapeutics has successfully completed a debt refinancing deal, allowing the biotechnology firm to restructure its financial obligations. This move comes amidst ongoing challenges with the...
Sarepta Therapeutics has successfully refinanced its debt, providing the biotech firm with a stronger financial footing as it navigates a complex regulatory landscape. This move comes...
